Immunotherapy News and Research

Latest Immunotherapy News and Research

Nanoparticle boost for antitumor vaccines

Researchers have known for some time that certain sequences of synthetic DNA induce potent immune responses when injected into animals and humans.

12 Feb 2007

Nventa Bio issued U.S patent for heat shock protein fusion to treat influenza

The patent provides coverage for compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins and their use in immunotherapy.

30 Jan 2007

Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells

Using a biodegradable nanoparticle as a means of delivering tumor cell debris and proteins to the immune system, investigators at Yale University have developed a promising new method for creating therapeutic anticancer vaccines.

29 Jan 2007

New cancer treatments use body's own immune system to kill melanoma tumours

Scientists are claiming that the body's own immune system could be used to fight the most serious form of skin cancer, malignant melanoma.

13 Nov 2006

New smart anti-microbial approach to preventing tooth decay

Preventing cavities could one day involve the dental equivalent of a military surgical strike. A team of researchers supported by the National Institute of Dental and Craniofacial Research report they have created a new smart anti-microbial treatment that can be chemically programmed in the laboratory to seek out and kill a specific cavity-causing species of bacteria, leaving the good bacteria untouched.

23 Oct 2006

CCR5 receptor discovery could help fight against tuberculosis, HIV

A key aspect of how the body kicks the immune system into action against tuberculosis is revealed in research published today.

20 Oct 2006

Super chow, laced with semi-synthetic vitamin E derivative, inhibited spread of cancer in mice

A chemically altered form of vitamin E mixed into mouse chow dramatically reduced spread of aggressive mammary cancer in mice, suggesting that the compound in pill form could be used to treat human metastatic cancer, according to a report in the October 1 issue of the journal Cancer Research.

2 Oct 2006

Immunotherapy for heart failure

World Congress of Cardiology Report - Heart failure (HF) is a complex, progressive clinical syndrome that can result from any structural or functional cardiac disorder, such as coronary artery disease or hypertension (high blood pressure), which impairs the ability of the heart to function properly as a pump.

5 Sep 2006

Induction of potent antitumor immunity by intratumoral injection of IL-23 transduced dendritic cells

One therapy for treating brain tumors alerts the immune system to the presence of foreign material. A second therapy enhances the first and prolongs the immune system's response.

4 Sep 2006

Teen wins right to refuse chemo

A teenager in the U.S. who has Hodgkins' Disease, has won a court battle which aimed to order the boy to undergo a second course of intensive chemotherapy.

20 Aug 2006

Some Yellow Jackets cause more severe allergic reactions than others

Allergists at Johns Hopkins School of Medicine have concluded that the sting severity is determined not by the calendar but by the species of insect doing the stinging.

15 Aug 2006

Turning the immune system against cancer

Medicine can now prevent a host of diseases with a mere shot of vaccine. Polio and smallpox are almost non-existent, and mumps and chicken pox are rarely seen nowadays.

4 Aug 2006

How does the immune system isolate and destroy intruders?

Dendritic cells are the body's "watchdogs". They recognize and then degrade pathogens, isolating characteristic fragments that are recognized by the immune system thus triggering targeted responses.

25 Jul 2006

Nexavar approved in Europe for treatment of advanced kidney cancer

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc have announced that the European Commission has granted marketing authorization to Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma.

24 Jul 2006

Biomira Stimuvax prostate cancer study results published

Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients

20 Jul 2006

Buckyballs deliver multiple drugs simultaneously to tumors

Combining a monoclonal antibody known to target melanoma tumors with multiple C60 buckyballs, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have developed a new way to deliver multiple drugs simultaneously to tumors.

3 Jul 2006

Sunitinib malate drug shows significant benefits over standard treatment for advanced kidney cancer

According to a new study, the drug sunitinib malate (Sutent.) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC).

5 Jun 2006

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

New way of targeting proteins to exosomes - potential for melanoma, Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have discovered how a protein called Pmel17 is sorted by pigment cells in the skin and eye to make a fiber matrix that eventually sequesters melanin, the dark pigment found in skin, hair, and eyes.

28 Mar 2006

Is there any role for thalidomide as a monotherapy in the management of metastatic renal cell carcinoma?

Thalidomide remains an enigma in the treatment of metastatic renal cell carcinoma (RCC). Initial clinical trials suggested a benefit, but more recently, subsequent randomized trials studying thalidomide in combination with other agents such as interferon have demonstrated no added benefit.

8 Mar 2006